Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Erratum: [Corrigendum] Engineered AXL<sup>-ECD</sup>-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration.

Oncology letters·2026
Same author

Plasma metabolic signature of cardiovascular-kidney-metabolic syndrome and incident stroke: A nationwide prospective cohort study.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

Pan-filovirus activity of an IGF2-fused monoclonal antibody: Impairment by IGF1R cross-engagement and rescue via IGF2 Y27L mutation.

Virus research·2026
Same author

Pathogen-Centric Activation of an Azoreductase-Responsive Antibody-Antibiotic Conjugate for the Targeted Eradication of MRSA.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Evaluating the efficacy of a telehealth management model for chronic diabetes in resource-constrained regions.

Frontiers in endocrinology·2026
Same author

Neuropsychiatric disorders in children of mothers with polycystic ovary syndrome: a systematic review and meta-analysis.

BMC psychiatry·2026

相关实验视频

Updated: Feb 22, 2026

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K

抗体查和绑定预测分析 准Stx2

Jilei Wu1, Chenghua Liu2, Fenghao Peng2

  • 1College of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212000, China.

Antibodies (Basel, Switzerland)
|February 20, 2026
PubMed
概括

两个单克隆抗体,YG12-1和YG12-2,在中和Siga毒素2 (Stx2) 方面表现有前途,这是严重大肠杆菌感染的关键因素. 虽然YG12-2结合更强,但YG12-1表现出优越的保护作用,突出显示复杂抗体的有效性.

关键词:
大肠杆菌O157:H7感染免疫建设者是免疫建设者.石加毒素2型 (Stx2) 是一种新型毒素.人类单克隆抗体结构预测结构预测

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K
Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
08:49

Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens

Published on: June 6, 2020

15.4K

相关实验视频

Last Updated: Feb 22, 2026

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K
Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
08:49

Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens

Published on: June 6, 2020

15.4K

科学领域:

  • 免疫学 免疫学 免疫学
  • 微生物学 微生物学
  • 结构生物学 结构生物学

背景情况:

  • 由肠出血性大肠杆菌 (EHEC) 生产的Shiga毒素 (Stx),特别是Stx2,是一种强有力的外毒毒素,会导致严重的疾病,如血清性尿素综合征 (HUS).
  • 目前对Stx2引起的并发症的治疗选择有限,需要开发新的治疗策略.

研究的目的:

  • 为了识别和表征人类单克隆抗体,准Shiga毒素2 (Stx2).
  • 评估 Stx2 中和抗体的结构和功能性质,以潜在的治疗应用.

主要方法:

  • 菌体显示库查以确定人类单克隆抗体YG12-1和YG12-2.
  • 综合计算建模 (ImmuneBuilder,Rosetta) 和实验验证 (ELISA,SPR) 以评估抗体-抗原相互作用.
  • 使用急性腹膜感染的小鼠模型进行体内疗效评估.

主要成果:

  • 结构分析显示,由于CDRH3拓较长和增强的静电互补性,YG12-2与Stx2具有优越的结合亲和力.
  • 尽管具有较高的结合亲和力,但YG12-1在小鼠感染模型中表现出更大的保护活性.
  • 观察到抗体亲和力和体内疗效之间的非线性相关性,受表皮质可访问性和药理动力学的影响.

结论:

  • 单克隆抗体YG12-1和YG12-2代表了针对Stx2介导的大肠杆菌O157:H7感染的潜在治疗策略.
  • 活体功能疗效是治疗成功的关键决定因素,超出了简单的结合亲和力.